Recap-BUZZ-Preview: Johnson & Johnson’s third-quarter earnings expected to decline

Reproduced the BUZZ report released on Monday, content unchanged

October 13 - ** Johnson & Johnson JNJ.N shares rose 0.6% on Monday to $263.00, as the market awaits its quarterly results to be announced before the opening, with investors closely watching the rebound of its MedTech segment

** According to LSEG data, the healthcare group is expected to report third-quarter revenue of $25.28 billion and adjusted earnings per share of $2.54, which is lower than the $2.80 per share a year earlier, but revenue has increased from $23.99 billion a year ago

** Last quarter (link), the company benefited from strong pharmaceutical sales, exceeding expectations, but its Abiomed heart pump business saw sales decline after a key UK study

** In September, an experimental antidepressant co-developed by the company and Contineum Therapeutics CTNM.O failed to meet its primary endpoint in a mid-stage study (link)

** Johnson & Johnson (JNJ) has met or exceeded market expectations for earnings per share and revenue in at least the last eight quarters

** Of the 26 analysts covering Johnson & Johnson, 19 rate it as “strong buy” or “buy,” and 7 as “hold”

** Over the past month, the median target price of $282 has remained unchanged

** JNJ shares have risen about 27% so far this year, outperforming the approximately 8% gain of the Dow Jones Industrial Average .DJI

(To assist non-native English speakers, Reuters offers automated translations of its reports into several other languages. As automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the automated translation, which is provided solely for the convenience of readers. Reuters accepts no responsibility for any damage or loss arising from the use of automated translation functions.)